Targeting nPKC-θ inhibited mesenchymal signatures in CTCs and allowed re-expression of key effector cytokines in CD8+ T cells in mouse tumor models and patient-derived cancer and immune cells. The gene discussed is CD8A; the disease is neoplasm.